Upstream Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Upstream Bio, Inc. on June 9, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Waltham, Massachusetts.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (April 13, 2026), 54,419,986 shares were outstanding. A quorum was established with 48,100,767 shares present virtually or by proxy. Stockholders approved two proposals:
- Proposal 1 (Election of Directors): Stockholders elected H. Edward Fleming, Jr., M.D., and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A., as Class II directors to serve until the 2029 annual meeting.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It serves solely to disclose the final voting results of the Annual Meeting.
Investor Verification Checklist
- Verify the final voting percentages for the election of H. Edward Fleming, Jr., and Liam Ratcliffe.
- Confirm the appointment of PwC as the independent auditor for the 2026 fiscal year.
- Review the Definitive Proxy Statement filed on April 16, 2026, for detailed biographies of the elected directors and further context on the proposals.
- Note that no financial metrics are disclosed in this specific 8-K filing.